Data from the phase III MAIA of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone in newly diagnosed, transplant-ineligible patients with multiple myeloma—regardless of patients’ age and across clinically important subgroups, as well as health-related quality of life among frail TIE patients—were presented in oral and poster presentations at the American Society of Hematology 2022 Annual Meeting.
Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
